[HTML][HTML] Early-stage non-small cell lung cancer: New challenges with immune checkpoint blockers and targeted therapies
P Lavaud, M Bortolot, L Zullo, D O'Reilly, J Naidoo… - Cancers, 2024 - mdpi.com
Simple Summary The current review summarizes the new potential treatment strategies for
patients with early-stage non-small cell lung cancer with immunotherapy and targeted …
patients with early-stage non-small cell lung cancer with immunotherapy and targeted …
Revolutionizing Localized Lung Cancer Treatment: Neoadjuvant Chemotherapy plus Immunotherapy for All?
V Ferrari, C Helissey - Journal of Clinical Medicine, 2024 - mdpi.com
Lung cancer poses a significant public health challenge, with resectable non-small cell lung
cancer (NSCLC) representing 20 to 25% of all NSCLC cases, staged between I and IIIA …
cancer (NSCLC) representing 20 to 25% of all NSCLC cases, staged between I and IIIA …
Spatially map** the tumour immune microenvironments of non-small cell lung cancer
Lung cancer is the leading cause of cancer-related deaths. An enhanced understanding of
the immune microenvironments within these tumours may foster more precise and efficient …
the immune microenvironments within these tumours may foster more precise and efficient …
SOX4-BMI1 axis promotes non-small cell lung cancer progression and facilitates angiogenesis by suppressing ZNF24
T Wen, X Zhang, Y Gao, H Tian, L Fan, P Yang - Cell Death & Disease, 2024 - nature.com
The incidence of lung cancer has become the highest among all cancer types globally, also
standing as a leading cause of cancer-related deaths. Lung cancer is broadly divided into …
standing as a leading cause of cancer-related deaths. Lung cancer is broadly divided into …
[HTML][HTML] Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression
S Wang, G Liu, L Yu, C Zhang… - Translational Lung …, 2024 - pmc.ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype,
presents significant treatment challenges. Cisplatin (CP)-based regimens are central to the …
presents significant treatment challenges. Cisplatin (CP)-based regimens are central to the …
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic …
Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has
improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC) …
improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC) …
Prognosis prediction using significant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors: A meta-analysis
F Nie, Y Wang, W Shi, L Zhu, J Hao, R Tao - Frontiers in Surgery, 2024 - frontiersin.org
Background A meta-analysis study was done to figure out how to predict the prognosis of
people with resectable non-small-cell lung cancer (NSCLC) who had a significant …
people with resectable non-small-cell lung cancer (NSCLC) who had a significant …
Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non–Small Cell Lung Cancer
L Zhang, J Li, L Guo - JAMA oncology, 2024 - jamanetwork.com
Results| Of 834 797 patients (53.0% male; median [IQR] age, 66 [56-76] years; race and
ethnicity, 3.7% Asian; 11.9% Black; 6.6% Hispanic; 0.6% Native and Pacific Islander; 81.8 …
ethnicity, 3.7% Asian; 11.9% Black; 6.6% Hispanic; 0.6% Native and Pacific Islander; 81.8 …
Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer
N Zhang, C Li, Z Zhao, B Jiang, W Wang… - Frontiers in …, 2025 - frontiersin.org
Background The therapeutic efficacy of neoadjuvant immunotherapy combined with
chemotherapy (Io+ Chemo) is superior than chemotherapy alone (Chemo). However, the …
chemotherapy (Io+ Chemo) is superior than chemotherapy alone (Chemo). However, the …
Outcomes After Neoadjuvant Therapy With or Without Immunotherapy Followed By Pneumonectomy in Non-Small Cell Lung Cancer Patients
Z Li, L Wu, C Wang, S Wang, Q Chen, W He - The Annals of Thoracic …, 2024 - Elsevier
Background There are limited data concerning pneumonectomy after preoperative induction
therapy. Our study aimed to evaluate feasibility and safety of pneumonectomy after …
therapy. Our study aimed to evaluate feasibility and safety of pneumonectomy after …